Nevertheless, various pieces of evidence show increased expression of PKCδ in AD patients (Du et al., 2018), pointing towards the fact that PKCδ inhibition plays an important protective role in brain aging (Conboy et al., 2009), ischemia (Bright et al., 2004; Dave et al., 2011; Phan et al., 2002), and neurodegenerative disease (Du et al., 2018; Kaul et al., 2005; Yang et al., 2004; Zhang et al., 2007). Here, PRKCD is linked to Alzheimer disease.